<?xml version='1.0' encoding='utf-8'?>
<document id="31817628"><sentence text="Are the Hydantoin-1,3,5-triazine 5-HT6R Ligands a Hope to a Find New Procognitive and Anti-Obesity Drug? Considerations Based on Primary In Vivo Assays and ADME-Tox Profile In Vitro."><entity charOffset="8-32" id="DDI-PubMed.31817628.s1.e0" text="Hydantoin-1,3,5-triazine" /></sentence><sentence text="Though the 5-HT6 serotonin receptor is an important target giving both agonists and antagonists similar therapeutic potency in the treatment of topic CNS-diseases, no 5-HT6R ligand has reached the pharmaceutical market yet due to the too narrow chemical space of the known 5-HT6R agents and insufficient &quot;drugability"><entity charOffset="17-26" id="DDI-PubMed.31817628.s2.e0" text="serotonin" /></sentence><sentence text="&quot; Recently, a new group of non-indole and non-sulfone hydantoin-triazine 5-HT6R ligands was found, where 3-((4-amino-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-yl)methyl)-5-methyl-5-(naphthalen-2-yl)imidazolidine-2,4-dione (KMP-10) was the most active member"><entity charOffset="31-37" id="DDI-PubMed.31817628.s3.e0" text="indole" /><entity charOffset="105-222" id="DDI-PubMed.31817628.s3.e1" text="3-((4-amino-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-yl)methyl)-5-methyl-5-(naphthalen-2-yl)imidazolidine-2,4-dione" /><pair ddi="false" e1="DDI-PubMed.31817628.s3.e0" e2="DDI-PubMed.31817628.s3.e0" /><pair ddi="false" e1="DDI-PubMed.31817628.s3.e0" e2="DDI-PubMed.31817628.s3.e1" /></sentence><sentence text=" This study is focused on wider pharmacological and &quot;druglikeness&quot; characteristics for KMP-10" /><sentence text=" A computer-aided insight into molecular interactions with 5-HT6R has been performed" /><sentence text=" &quot;Druglikeness&quot; was examined using an eight-test panel in vitro, i" /><sentence text="e" /><sentence text=", a parallel artificial membrane permeability assay (PAMPA), and Caco-2 permeability-, P-glycoprotein (Pgp) affinity-, plasma protein binding-, metabolic stability- and drug-drug interaction-assays, as well as mutagenicity- and HepG2-hepatotoxicity risk tests" /><sentence text=" Behavioral studies in vivo, i" /><sentence text="e" /><sentence text=", elevated plus-maze (EPM) and novel object recognition (NOR) tests, were performed" /><sentence text=" Extended studies on the influence of KMP-10 on rats' metabolism, including biochemical tests, were conducted in vivo" /><sentence text=" Results indicated significant anxiolytic and precognitive properties, as well as some anti-obesity properties in vivo, and it was found to satisfy the &quot;druglikeness&quot; profile in vitro for KMP-10" /><sentence text=" The compound seems to be a good lead-structure and candidate for wider pharmacological studies in search for new CNS-drugs acting via 5-HT6R" /><sentence text="" /></document>